PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer

Resistance to PARP inhibitors (PARPi) remains a therapeutic challenge in ovarian cancer patients. PDZ-binding kinase (PBK) participates in the chemoresistance of many malignancies. However, the role of PBK in PARPi resistance of ovarian cancer is obscure. In the current study, we demonstrated that o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hanlin, Qi, Gonghua, Han, Fang, Peng, Jiali, Yuan, Cunzhong, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355941/
https://www.ncbi.nlm.nih.gov/pubmed/35859118
http://dx.doi.org/10.1038/s12276-022-00809-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355941/
https://www.ncbi.nlm.nih.gov/pubmed/35859118
http://dx.doi.org/10.1038/s12276-022-00809-w

Ejemplares similares